Dietary combination of soy with a probiotic or prebiotic food significantly reduces total and LDL cholesterol in mildly hypercholesterolaemic subjects

被引:59
作者
Larkin, T. A. [1 ,2 ]
Astheimer, L. B. [1 ,2 ]
Price, W. E. [2 ,3 ]
机构
[1] Univ Wollongong, Dept Biomed Sci, Wollongong, NSW 2522, Australia
[2] Univ Wollongong, ARC, Smart Foods Key Ctr, Wollongong, NSW 2522, Australia
[3] Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia
基金
澳大利亚研究理事会;
关键词
isoflavones; probiotic; prebiotic; lipids; bioavailability; equol; FERMENTED MILK PRODUCT; IMPROVE PLASMA-LIPIDS; GUT MICROFLORA; LACTOBACILLUS-ACIDOPHILUS; CARDIOVASCULAR-DISEASE; INTESTINAL MICROFLORA; RESISTANT STARCH; BLOOD-LIPIDS; RISK-FACTORS; ISOFLAVONES;
D O I
10.1038/sj.ejcn.1602910
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Objective: We hypothesized that a dietary combination of soy with either a probiotic (yoghurt) or a prebiotic (resistant starch) would result in enhanced lipid-lowering effects compared with a control soy diet, possibly via improvements in isoflavone bioavailability. Subjects: Mildly hypercholesterolaemic subjects (men and post-menopausal women) older than 45 years were recruited via the local media. Thirty-six subjects commenced the study; five withdrew. Results: Soy + probiotic significantly decreased total cholesterol (4.7 +/- 2.0%; P=0.038) and soy + prebiotic significantly decreased total and low-density lipoprotein cholesterol (5.5 +/- 1.6%; P=0.003 and 7.3 +/- 2.2%; P=0.005, respectively). The bioavailabilities of daidzein, genistein or equol were not affected by probiotic or prebiotic consumption or associated with lipid changes. Conclusion: Dietary combination of soy with either a probiotic or a prebiotic resulted in significant lipid lowering, not related to isoflavone bioavailability.
引用
收藏
页码:238 / 245
页数:8
相关论文
共 46 条
[21]   Colonic bacterial activity and serum lipid risk factors for cardiovascular disease [J].
Jenkins, DJA ;
Vuksan, V ;
Rao, AV ;
Vidgen, E ;
Kendall, CWC ;
Tariq, N ;
Würsch, P ;
Koellreutter, B ;
Shiwnarain, N ;
Jeffcoat, R .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (02) :264-268
[22]  
LARKIN T, 2005, THESIS U WOLLONGONG
[23]   Soy protein, isoflavones and cardiovascular disease risk [J].
Lichtenstein, AH .
JOURNAL OF NUTRITION, 1998, 128 (10) :1589-1592
[24]  
Merz-Demlow BE, 2000, AM J CLIN NUTR, V71, P1462
[25]   Modulation of fecal markers relevant to colon cancer risk: a high-starch Chinese diet did not generate expected beneficial changes relative to a western-type diet [J].
Muir, JG ;
Walker, KZ ;
Kaimakamis, MA ;
Cameron, MA ;
Govers, MJAP ;
Lu, ZX ;
Young, GP ;
O'Dea, K .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 68 (02) :372-379
[26]   Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women [J].
Nestel, PJ ;
Yamashita, T ;
Sasahara, T ;
Pomeroy, S ;
Dart, A ;
Komesaroff, P ;
Owen, A ;
Abbey, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (12) :3392-3398
[27]   Screening of intestinal microflora for effective probiotic bacteria [J].
O'Sullivan, DJ .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2001, 49 (04) :1751-1760
[28]  
Parodi PW, 1999, AUST J DAIRY TECHNOL, V54, P103
[29]   Effects of consumption of probiotics and prebiotics on serum lipid levels in humans [J].
Pereira, DIA ;
Gibson, GR .
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2002, 37 (04) :259-+
[30]   Soy protein and cardiovascular disease: The impact of bioactive components in soy [J].
Potter, SM .
NUTRITION REVIEWS, 1998, 56 (08) :231-235